---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-25-034793"
form_type: "8-K"
ticker: "CTSO"
cik: "0001175151"
company_name: "Cytosorbents Corp"
filed_at: "2025-04-15T23:59:59+00:00"
generated_at: "2026-05-23T14:14:10.130060+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.45
calibrated_materiality_score: 0.45
confidence: "high"
source: SEC EDGAR
---

# CytoSorbents appoints Thomas Shannon as VP of Marketing for North America ahead of DrugSorb-ATR launch

## Summary
- Thomas Shannon appointed VP of Marketing, North America; will lead strategy for DrugSorb-ATR in U.S. and Canada.
- Shannon has 25+ years commercializing cardiovascular and critical care devices at Fresenius, Getinge, Medtronic.
- DrugSorb-ATR is an FDA Breakthrough device for perioperative bleeding in CABG patients on Brilinta; regulatory decisions expected in 2025.
- CEO Dr. Phillip Chan highlights Shannon's expertise as 'invaluable' for commercialization as company awaits FDA/Health Canada approvals.

## SEC filing metadata
- accession: 0001104659-25-034793
- form_type: 8-K
- ticker: CTSO
- cik: 0001175151
- company_name: Cytosorbents Corp
- filed_at: 2025-04-15T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.45
- calibrated_materiality_score: 0.45
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1175151/000110465925034793/0001104659-25-034793-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1175151/000110465925034793/tm2512296d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-25-034793
- JSON: https://secwatch.observer/filing/0001104659-25-034793.json
- Plain text: https://secwatch.observer/filing/0001104659-25-034793.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.